US biotech firm Guardant Well being (Nasdaq: GH) has acquired Israeli exact liquid biopsy firm MetaSight Diagnostics for a direct fee of $59 million and an extra $90 million in milestone funds. The acquisition was revealed in Guardant Well being’s fourth quarter outcomes. The milestone funds embrace receiving regulatory approvals and gross sales thresholds. The corporate has developed exams for correct early prognosis of most cancers that might value only some {dollars}.
MetaSight was based by Prof. Tomer Shlomi from the Technion along with aMoon Fund as a part of the aMoon Velocity program. The corporate makes use of multiomics applied sciences, to investigate cells utilizing completely different approaches, and mixing data with AI, to diagnose colon most cancers and metabolic problems in liver operate. The know-how is within the medical trial stage.
The corporate developed the know-how primarily based on the Maccabi Well being Fund database.
The exit is modest however supplies quick and good-looking returns for aMoon.. MetaSight was based in 2020 and has raised $20 million thus far. Amongst its buyers are the US fund ARC and Saban Ventures. The corporate has workplaces in Rehovot that may turn out to be Guardant’s first growth website in Israel.
Dr. Yaron Daniely, who leads the aMoon Velocity program, tells “Globes,” “Guardant is a number one firm within the discipline of most cancers prognosis utilizing superior strategies. Their market worth is about $13.7 billion they usually recorded income of a few billion {dollars} this yr.”
Discovered a standard language
How did the connection with the corporate come about?
“Guardant acknowledged the corporate’s benefits after we introduced our exams at conferences that allow fast prognosis at costs of some {dollars} per check. They talked about of their convention name that that they had reviewed dozens of firms within the discipline and selected our know-how from them.”
“We additionally selected them,” provides Dr. Daniely, “We obtained inquiries from a number of firms. With Guardant, we discovered frequent floor. The corporate’s cofounders and co-CEOs Helmy Eltoukhy and AmirAli Talasaz, are former Iranians, so there was a cultural connection between us. They based the corporate in 2012 and nonetheless function it with an entrepreneurial strategy. They significantly worth the corporate’s workers in Israel, and because the acquisition, they’ve employed workers and expanded the laboratory. That is their first growth heart not solely in Israel, however that is the primary time they’ve outdoors the US.”
Nevertheless, Danieli says with a smile: “That does not imply that the negotiations had been simple.”
How was the corporate based?
“Prof. Shlomi approached us after creating a way to considerably cut back the associated fee and pace up diagnostics utilizing a mass spectrometer. This technique allowed us to diagnose samples at very excessive resolutions. We teamed up with Maccabi and created a database of almost 1,000,000 samples coded utilizing the MetaSight technique. Primarily based on this, we developed the colon most cancers check.
“The check is about two to 3 years away from finishing medical trials, and if these are profitable, then the extra quantity might be paid within the deal.”
Printed by Globes, Israel enterprise information – en.globes.co.il – on February 21, 2026.
© Copyright of Globes Writer Itonut (1983) Ltd., 2026.
